Infectious Diseases

The federal agency advised manufacturers in June that 2024-2025 COVID-19 vaccines should be monovalent JN.1, with the preferred lineage being the KP.2 strain.

Healthcare providers should maintain heightened suspicion of parvovirus B19 in individuals presenting with symptoms, particularly those at high risk.

Among children born in 2020, vaccination coverage was 4 to 14 percentage points lower among those who were eligible for VFC versus non-eligible children.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.

As of July 19, 2024, there were 28 Listeria illnesses and 2 deaths linked to meats sliced at delis.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Despite extensive efforts, there remains no approved vaccine for norovirus, HilleVax decided to focus on a different development, a Phase 1 ready vaccine candidate for adults.

Donna Hallas. PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, underscores the critical need for proper vaccination and effective communication between parents and schools to ensure sick children stay home, while addressing logistical challenges faced by parents.

Matthew M Davis, MD, MAPP, elaborates on how higher COVID-19 vaccination rates may curb the virus, alleviate childhood asthma symptoms, and protect against other common colds.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

Results confirmed that a bedaquiline-containing regimen offered a significant improvement in treatment outcomes compared to injectable-containing regimens.

Matthew M. Davis, MD, MAAP, breaks down a newly-published study highlighting a potential association between COVID-19 vaccination and prevalence of symptomatic childhood asthma.

Experts highlight common waterborne illnesses, preventive tips for summer.

Unexpected seasonal RSV following COVID-19 highlighted the need for ongoing research to better understand transmission and ongoing impact from the pandemic.

Over the winter, the omicron JN.1 lineages overtook XBB strains as dominant.

The 2 groups did not differ in how likely they were to fill at least 1 prescription of any antibiotic while enrolled in kindergarten.

Management of ICEP with monoclonal antibodies against IL-5 and IgE (omalizumab) could be promising according to study authors, though extent of evidence is lacking.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the June 2024 issue of Contemporary Pediatrics.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

The program allows participants to reserve doses and be eligible for priority shipping, among other benefits.

Courtney Nelson, MD, highlights the session she presented at the PAS annual meeting discussing racial and ethnic disparities for influenza vaccine delivery.

In a time when vaccine hesitancy is contributing to a rise in measles cases, an understanding of why parents are hesitant is key to help change their narrative.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April 2024 issue of Contemporary Pediatrics.

The new data, published in The Lancet, showed that nirsevimab substantially reduced RSV hospitalizations.

ICD-10 accuracy varied by age of the patient, influenza season definition, time between onset and testing, and clinical setting.

New cohort analyses observe a statistically raised risk of myocarditis, pericarditis and seizures among certain age groups, though the data do not go against FDA recommendations.

Cohort analysis shows the rate of RSV hospitalizations among children up to 5 years old skyrocketed in 2021—and then nearly doubled again in 2022—compared to pre-pandemic rates.

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.

New data demonstrates protection against new variants.